Compare GHG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | LUNG |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 57.9M |
| IPO Year | 2017 | 2020 |
| Metric | GHG | LUNG |
|---|---|---|
| Price | $1.15 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 7.7K | ★ 568.9K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $19.02 | $2.48 |
| Revenue Next Year | $8.26 | $18.46 |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $1.11 | $1.13 |
| 52 Week High | $2.78 | $3.88 |
| Indicator | GHG | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 50.96 |
| Support Level | $1.14 | $1.22 |
| Resistance Level | $1.16 | $1.45 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 80.00 | 53.12 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.